Study shows why immune-boosting therapy doesn't work for everyone with widespread melanoma

(NYU Langone Medical Center / New York University School of Medicine) Patients who don't respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to study results presented at the annual meeting of the American Society for Clinical Oncology (ASCO) on June 4, 2016 in Chicago.